Skip to main content

Branded

  • Solesta approved by FDA as fecal incontinence treatment

    SILVER SPRING, Md. — The Food and Drug Administration has approved an injectable gel for fecal incontinence, the agency said.

    The FDA announced the approval of Oceana Therapeutics’ Solesta for patients who have involuntarily lost bowel control and for whom such therapies as diet change, fiber therapy and antimotility medications have failed.

    Fecal incontinence affects more than 5.5 million Americans, according to the National Institutes of Health.

  • Lilly executive joins Chiquita's board

    CINCINNATI — An Eli Lilly executive was elected to Chiquita's board of directors at the company's annual shareholders meeting.

    Chiquita said that Jeffrey Simmons, who serves as Lilly SVP and president of the drug maker's animal health division, Elanco Animal Health, brings more than 20 years of management experience to his new role on the audit committee and the food innovation, safety and technology committee.

  • Sanofi: Lyxumia won't significantly increase hypoglycemia risk

    PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

  • Dificid gets nod as CDAD treatment

    SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

    The agency announced the approval of Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea, also known as CDAD.

  • Court grants Amylin temporary restraining order to bar Lilly from using same sales team

    SAN DIEGO — Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

  • J&J looks to boost product portfolio, seeks regulatory approval for 11 new drugs

    NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.

  • Biogen Idec introduces Women in MS educational initiative

    WESTON, Mass. — Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

  • Many caregivers forgo their own medication adherence, research finds

    WOONSOCKET, R.I. — Many people who provide care and support to loved ones said they are more likely to be nonadherent to their own personal medication regimen than to neglect providing medications to those they are caring for, according to a new study by researchers at Harvard University, Brigham and Women's Hospital and CVS Caremark. Given this, there's a significant opportunity for pharmacists and doctors to identify and work with caregivers to improve medication adherence and chronic disease management.

X
This ad will auto-close in 10 seconds